@entity817 XXXX mutation in neocortical posterior temporal @entity7667 .

@entity1 @entity410 @entity1625 @entity5 @entity8554 @entity302 @entity10067 @entity817 @entity7667
UNASSIGNED: The aim of this study was to verify the presence of @entity817 mutations in a series of six @entity1 affected by drug-resistant @entity1625 associated with @entity7667 (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of @entity302 and represent the most common @entity5 in young @entity1 undergoing surgery for intractable @entity1625 . @entity817 mutations have been identified in up to 50% of GG. Interestingly, these six @entity1 shared a specific anatomical posterior temporal site. In all @entity1 , histological examination confirmed the diagnosis of GG, and two were also associated with a @entity10067 ( @entity10067 ) type IIa. @entity817 mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of @entity1 2 showed a concomitant @entity817 @entity8554 mutation. All @entity1 but one (83.3%) achieved Engel Class Ia @entity410 control. The @entity1 carrying a concomitant @entity817 mutation in GG and @entity10067 fell into Engel Class II. Further analyses will be required in order to better understand the meaning of @entity817 mutations in @entity5 and @entity10067 and their possible role as a prognostic @entity410 outcome and @entity5 behavior marker.
